Healthcare / Drug Manufacturers - Specialty & GenericBSE
$42.69
-1.40 (-3.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $104000.00 · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$412M
P/E
23.3x
↑EV/EBITDA
10.4x
↓ROE
4.0%
↑Gross Margin
54.9%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
—
FCF margin
7.7%
FCF / Net income
3.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $699.3M · net income $17.7M · FCF $54.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $699.3M | $699.3M | $671.9M | $672.8M | $653.5M |
| Net Income | $17.7M | $17.7M | $15.5M | $14.6M | $15.2M |
| EBITDA | $34.4M | $34.4M | $29.3M | $27.1M | $28.1M |
| EPS | — | — | 1.60 | 1.51 | 1.62 |
| Gross Margin | 54.9% | 54.9% | 52.2% | 49.8% | 50.6% |
| Operating Margin | 3.3% | 3.3% | 3.1% | 2.5% | 3.0% |
| Net Margin | 2.5% | 2.5% | 2.3% | 2.2% | 2.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.00 | — |
| Current Ratio | 2.43 | 2.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $54.0M | $54.0M | $104000.00 | $-6.7M | $-8.5M |
| Returns | |||||
| ROE | 4.0% | 4.0% | 3.7% | 3.6% | 3.9% |
| Valuation | |||||
| P/E | 23.33 | 23.33 | 28.16 | 42.38 | 34.80 |
| EV/EBITDA | 10.38 | 10.38 | 14.59 | 22.46 | 18.14 |
| P/B | 0.94 | 0.94 | 1.04 | 1.52 | 1.36 |
| Growth & Yield | |||||
| Revenue Growth | 4.1% | 4.1% | -0.1% | 3.0% | — |
| EPS Growth | — | — | 6.0% | -6.8% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.2%
Start / end P/E
n/dx → n/dx
EPS bridge
1.60 → n/d
Residual
-25.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.